Lee J H, Machtay M, Unger L D, Weinstein G S, Weber R S, Chalian A A, Rosenthal D I
Department of Radiation Oncology, University of Pennsylvania Medical Center, Philadelphia 19104, USA.
Arch Otolaryngol Head Neck Surg. 1998 Aug;124(8):871-5. doi: 10.1001/archotol.124.8.871.
Most patients receiving accelerated fractionation radiotherapy or chemoradiotherapy for head and neck cancer experience severe mucositis. This can lead to decreased oral intake, resulting in dehydration, severe malnutrition, hospitalization, and/or interruption of radiotherapy.
To evaluate the effect of prophylactic gastrostomy tubes (PGTs) on the rates of weight loss, unplanned interruptions, and hospitalization during high-intensity head and neck radiotherapy.
A retrospective review was performed on 88 patients treated for locally advanced head and neck cancer with accelerated twice-a-day radiation (n = 59) or concurrent chemoradiotherapy (n = 29). Prophylactic gastrostomy tubes were placed in 36 (41%) of patients in anticipation of increased acute toxic effects from treatment. The remaining patients without PGTs served as a control group.
Patients without PGTs lost an average 3.1 kg compared with 7.0 kg in the control group (P<.001). There were significantly fewer hospitalizations for nutritional or dehydration issues in those with PGTs than in the control group (13% vs 34%; P = .04, chi2 test). Among those with good performance status, no patient with a PGT required a treatment interruption, compared with 18% of patients without a PGT (P = .08). Sixteen patients (31%) in the control group underwent therapeutic gastrostomy tube placement during or after radiation therapy.
The use of PGTs significantly reduces weight loss and the rate of hospitalization for dehydration and complications of mucositis. Treatment interruptions may also be avoided by the use of PGTs in patients with good performance status. We encourage patients scheduled for intensive radiation therapy to receive a PGT.
大多数接受头颈部癌加速分割放疗或放化疗的患者会出现严重的黏膜炎。这可能导致经口摄入量减少,进而引起脱水、严重营养不良、住院和/或放疗中断。
评估预防性胃造瘘管(PGT)对高强度头颈部放疗期间体重减轻率、计划外中断及住院情况的影响。
对88例接受局部晚期头颈部癌治疗的患者进行回顾性分析,这些患者接受每日两次加速放疗(n = 59)或同步放化疗(n = 29)。鉴于治疗会增加急性毒性反应,36例(41%)患者放置了预防性胃造瘘管。其余未放置PGT的患者作为对照组。
未放置PGT的患者平均体重减轻3.1 kg,而对照组为7.0 kg(P <.001)。放置PGT的患者因营养或脱水问题住院的次数明显少于对照组(13% 对34%;P = .04,卡方检验)。在身体状况良好的患者中,放置PGT的患者均无需中断治疗,而未放置PGT的患者中有18%需要中断治疗(P = .08)。对照组有16例患者(31%)在放疗期间或放疗后接受了治疗性胃造瘘管置入。
使用PGT可显著减轻体重,降低因脱水和黏膜炎并发症而住院的发生率。对于身体状况良好的患者,使用PGT还可避免治疗中断。我们鼓励计划接受强化放疗的患者置入PGT。